Latest News

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

As Gulf markets ended mixed ahead of an anticipated U.S. Federal Reserve interest rate cut, the region's financial landscape is experiencing a nuanced interplay of economic indicators and market sentiment. With oil prices hovering near multi-month lows and expectations of monetary easing influencing regional economies, investors are keenly observing small-cap stocks for potential opportunities amidst these dynamic conditions. In this context, identifying promising stocks involves evaluating...

It is hard to get excited after looking at Frasers Group's (LON:FRAS) recent performance, when its stock has declined...

Looking at P/F Bakkafrost's ( OB:BAKKA ) insider transactions over the last year, we can see that insiders were net...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Mercury General (MCY) has quietly turned into a strong insurance rebound story, with the stock up about 36% year to date and roughly 18% over the past 3 months, catching value-focused investors attention. See our latest analysis for Mercury General. That 35.8% year to date share price return, alongside a 3 year total shareholder return of about 175.5%, suggests investors are steadily warming to Mercury General again as underwriting results and sentiment improve around property and auto...

Restructuring move puts Dentsu Soken in focus Dentsu Soken (TSE:4812) just signed off on a sizable internal shake up, with its board approving an organizational restructuring effective January 1, 2026, a move that naturally draws investor attention. See our latest analysis for Dentsu Soken. The 35.4% year to date share price return and 35.7% one year total shareholder return suggest momentum has been building, and this restructuring looks like the next deliberate step in that growth story...

Brighthouse Financial (BHF) has quietly outpaced the broader insurance space over the past year, climbing roughly 30% while still trading almost flat over the past month. This combination sets up an interesting entry point. See our latest analysis for Brighthouse Financial. Over the past year, Brighthouse Financial’s roughly 30% total shareholder return has been driven by improving earnings trends and steadier credit markets, even as its recent share price momentum has cooled near 65...

CubeSmart (CUBE) just delivered a mixed Q3 2025 update, missing slightly on earnings but topping revenue forecasts and lifting guidance again, while analysts split on what that means for growth from here. See our latest analysis for CubeSmart. The Q3 update lands after a choppy stretch, with the share price down about 11% over three months and the 1 year total shareholder return near minus 20%, suggesting momentum has cooled even as guidance and urban demand stay supportive. If CubeSmart's...

Zymeworks recently received FDA approval for its first internally developed therapy, zanidatamab, for HER2-positive biliary tract cancer, while also reporting clinical progress across its antibody-drug conjugate pipeline. This approval, alongside new supportive analyst coverage, marks a shift toward a royalty-focused, capital-light model that could reshape how investors assess Zymeworks' long-term earnings potential. Now we’ll explore how zanidatamab’s FDA approval, as Zymeworks’ first...

Tokyu Fudosan Holdings (TSE:3289) just launched Climate and Nature Linked Bonds, Japan’s first sustainability linked issue aligned with ICMA guidelines, a financing move that ties its cost of capital directly to environmental performance. See our latest analysis for Tokyu Fudosan Holdings. The market seems to be rewarding this sustainability push, with a roughly 50 percent year to date share price return and a 5 year total shareholder return above 200 percent, suggesting momentum is still...

RioCan Real Estate Investment Trust (TSX:REI.UN) just set the stage for a fresh set of eyes on its books, approving PricewaterhouseCoopers as external auditor for 2026 after nearly 20 years with Ernst & Young. See our latest analysis for RioCan Real Estate Investment Trust. The governance refresh comes as the units trade around CA$18.25, with recent share price returns slightly negative over the past quarter while the one year total shareholder return has been solidly positive, hinting at...

Coinbase Global (COIN) has been quietly recalibrating after a choppy few months, with the stock slipping about 11% over the past month and 14% over the past 3 months, even as crypto volumes remain active. See our latest analysis for Coinbase Global. Step back from the recent pullback and Coinbase still looks like a name where sentiment is resetting rather than collapsing. The stock has delivered a modest year to date share price return alongside a powerful three year total shareholder return,...

User attention on T. Rowe Price Group (TROW) is picking up again as fresh analyst commentary zeroes in on familiar headwinds, from ongoing fund outflows to fee pressure, raising questions about what actually drives upside from here. See our latest analysis for T. Rowe Price Group. Despite the cautious analyst tone and leadership changes in its Asia Pacific institutional business, T. Rowe Price Group's share price at $104.52 reflects fading momentum, with a negative year to date share price...

SAP (XTRA:SAP) has been drifting lower in recent months, and that pullback is starting to catch investor attention. With shares down double digits year to date, the key question is whether fundamentals still justify a fresh look. See our latest analysis for SAP. That slide in the share price, now around $210.1, comes after a strong multi year run. Recent weakness suggests momentum has cooled as investors reassess growth expectations and macro risk, even though the three year total shareholder...

Earlier this year, Centessa Pharmaceuticals reported strong Phase 2 results for its sleep disorder drug ORX750, while also launching a US$250,000,000 public offering of 11.6 million American Depositary Shares and disclosing a US$300,000 insider share sale by Mario Alberto Accardi, President of the Orexin Program. The promising ORX750 data highlight Centessa’s effort to build a focused sleep-disorder franchise, even as it raises fresh capital and an insider trims holdings. We’ll now examine...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...

Key Insights The considerable ownership by public companies in Honeywell Automation India indicates that they...

Key Insights Institutions' substantial holdings in Rolls-Royce Holdings implies that they have significant influence...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Key Insights Significant control over Kolon Life Science by individual investors implies that the general public has...